The virosomal influenza vaccine Invivac®:: Immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad®) in elderly subjects
The virosomal influenza vaccine Invivac®:: Immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad®) in elderly subjects
复制标题
DOI：
10.1016/j.vaccine.2006.05.035
复制
发表时间：
2006-11-10
期刊：
影响因子：
5.5
通讯作者：
Palache, A. M.
中科院分区：
文献类型：
--
作者：
de Bruijn, I. A.;Nauta, J.;Palache, A. M.
目前正在寻求几种方法，以提高流感疫苗在老年人和对常规流感疫苗免疫反应受损的其他人中的效力。有两种流感疫苗可供老年患者使用：Fluad(R)(ChIron)和Invivac(R)(Solvay PharmPharmticals)。目前的临床研究是在61岁及以上的老年受试者中进行的一项随机、终点盲、平行分组研究，目的是与标准流感疫苗Invivac(R)(Solvay PharmPharmticals)进行比较，以调查这些疫苗的安全性和免疫原性。三种疫苗的免疫原性结果相似，但Invivac的耐受性比Fluad好。(C)2006爱思唯尔有限公司。保留所有权利。
Several approaches are currently being pursued in order to improve the efficacy of influenza vaccines in elderly individuals and others who have impaired immune responses to conventional influenza vaccines. There are two influenza vaccines available for elderly subjects: Fluad (R) (Chiron) and Invivac (R) (Solvay Pharmaceuticals). The present clinical study was a randomized, endpoint-blind, parallel group study in elderly subjects aged 61 years and older to investigate the safety and immunogenicity of these vaccines as compared to a standard influenza vaccine Invivac (R) (Solvay Pharmaceuticals). The three vaccines had similar immunogenicity results, whereas the tolerability profile of Invivac was better as compared to Fluad. (c) 2006 Elsevier Ltd. All rights reserved.